federal government tracks and reports quality and safety measures from 11 of the largest cancer hospitals in the country, including Dana-Farber. The measures included
here will become available on the hospital compare site in 2015 and 2016.
Process of Care Measures: Dana-Farber follows evidence-based approaches to caring for patients. For diseases that have an established and proven treatment pathway, Dana-Farber measures compliance with the proven standard of care.
- National Quality Foundation endorsed measure #0220: Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or Stage II or III hormone receptor positive breast
- National Quality Foundation endorsed measure #0223: Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer
- National Quality Foundation endorsed measure #0559: Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer
Infection Control Measures: Dana-Farber has an intensive infection control program. On our inpatient units, particular attention is paid to the measurement and prevention of two federally reported measures:
- Central Line Associated Blood Stream Infections (CLABSI) - Rate of Nosocomial CLASBI per 1,000 Central Line Days in All Patients*
- Catheter Associated Urinary Tract Infections - rate of UTIs per 1,000 Catheter Days in All Patients*
*Publicly reported infection rates are for Dana-Farber inpatient beds only.
Learn more about our Publicly Reported Measures.